Oculis Holding AG
NASDAQ:OCSBiotechnology
-$0.28 today
- Market cap
- $459.29M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
Volume 0.15M
Average 0.65M
Returns on capital
Oculis Holding AG management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-48.1%
avg -26.0%
ROIC
-39.6%
avg -78.9%
ROA
-40.0%
avg -69.3%
Analysis
ROIC is currently the strongest return metric at -39.6% versus its period average of -78.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Ramin Tadayoni | Chief Scientific Officer | — | — | — | — |
Riad Sherif | Chief Executive Officer & Director | — | 58 | — | — |
Sharon Klier | Chief Development Officer | — | — | — | — |
Snehal Shah | President of Research & Development | — | — | — | — |
Isabelle de Chambrier | Senior Vice President of Quality | — | — | — | — |
Rebecca Weil | Chief Commercial Officer | — | — | — | — |
Sylvia Cheung | Chief Financial Officer | — | 51 | — | — |
Virginia R. Dean | Chief Human Resources Officer | — | 60 | — | — |
Páll Ragnar Jóhannesson | Chief Business Officer | — | 44 | — | — |
Gudrun Bachmann | Chief Technology Officer | — | — | — | — |
Katie Kazem | Chief Legal Officer | — | — | — | — |
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Oculis Holding AG compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about OCS's management, answered from reported figures.
Who manages OCS?
Oculis Holding AG (OCS) lists 11 active executives. The top listed executive is Ramin Tadayoni, Chief Scientific Officer.
Continue the stock analysis
Jump to another research area for this company.